Business Development Licensing Protein 
The Pharma Data
JUNE 7, 2023
a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.
pharmaphorum
AUGUST 24, 2020
With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development team has agreed to buy Canadian biotech Forbius and its pipeline of drugs for cancer and fibrotic diseases.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 8, 2020
Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases.
The Pharma Data
NOVEMBER 10, 2020
These data support the continued development of drug candidates within the Alzstatin platform for early treatment of Alzheimer’s disease. Within the Alzstatin platform innovative disease-modifying and preventive drugs for Alzheimer’s disease are under development. 42 out from a longer protein known as APP.
The Pharma Data
AUGUST 3, 2021
Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. In the second quarter of 2021, the company recognized acquired in-process research and development charges of $25.0
The Pharma Data
AUGUST 3, 2021
Research & Development (R&D) expenses increased 12% primarily due to higher research and early pipeline spend and late-stage development program spend, including our recent business development activities. Acquired IPR&D expenses in 2021 were driven by the Five Prime Therapeutics acquisition. Tezepelumab.
XTalks
AUGUST 2, 2023
They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells).
Expert insights. Personalized for you.
40 
Let's personalize your content